Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin

Table 2 Duration of follow-up and characteristics of treatment according to final virological response

	All n = 113	SVR n = 37	Non SVR n = 76	P1
Follow-up from the first liver biopsy (mean ± SD, yr)	8.2 ± 3.1	8.2 ± 2.7	8.2 ± 3.3	0.7
Follow-up from the beginning of first treatment (mean ± SD, yr)	7.7 ± 3.0	7.7 ± 2.6	7.6 ± 3.1	0.6
Number of treatment courses				0.25
1	50 (44.2%)	19 (51.4%)	31 (40.8%)
2	42 (37.2%)	15 (40.5%)	27 (35.5%)
3	19 (16.8%)	3 (8.1%)	16 (21.1%)
4	2 (1.8%)	0 (0.0%)	2 (2.6%)
Type of treatment				1.00
α-interferon monotherapy	35 (31.0%)	11 (29.7%)	24 (31.6%)
Bitherapy	78 (69.0%)	26 (70.3%)	52 (68.4%)
Type of bitherapy				< 0.0001
α-interferon + ribavirin	40 (51.3%)	22 (84.6%)	18 (34.6%)
Peg-interferon + ribavirin	38 (48.7%)	4 (15.4%)	34 (65.4%)
Total duration of treatment (mo)	15.3 ± 9.05	14.3 ± 6.4	15.8 ± 10.1	0.4

SVR: Sustained virological response. ¹P values were obtained between SVR and non SVR groups.